0001209191-21-039632.txt : 20210610 0001209191-21-039632.hdr.sgml : 20210610 20210610185504 ACCESSION NUMBER: 0001209191-21-039632 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210608 FILED AS OF DATE: 20210610 DATE AS OF CHANGE: 20210610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ELMS STEVE CENTRAL INDEX KEY: 0001250195 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37939 FILM NUMBER: 211009442 MAIL ADDRESS: STREET 1: 888 SEVENTH AVE STREET 2: 29TH FL CITY: NEW YORK STATE: NY ZIP: 10106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Marker Therapeutics, Inc. CENTRAL INDEX KEY: 0001094038 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880277072 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3200 SOUTHWEST FREEWAY STREET 2: SUITE 2500 CITY: HOUSTON STATE: TX ZIP: 77027 BUSINESS PHONE: (713) 400-6400 MAIL ADDRESS: STREET 1: 3200 SOUTHWEST FREEWAY STREET 2: SUITE 2500 CITY: HOUSTON STATE: TX ZIP: 77027 FORMER COMPANY: FORMER CONFORMED NAME: TAPIMMUNE INC. DATE OF NAME CHANGE: 20170629 FORMER COMPANY: FORMER CONFORMED NAME: TAPIMMUNE INC DATE OF NAME CHANGE: 20070628 FORMER COMPANY: FORMER CONFORMED NAME: GENEMAX CORP DATE OF NAME CHANGE: 20020718 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-08 0 0001094038 Marker Therapeutics, Inc. MRKR 0001250195 ELMS STEVE C/O MARKER THERAPEUTICS, INC. 3200 SOUTHWEST FREEWAY, SUITE 2500 HOUSTON TX 77027 1 0 0 0 Common Stock 2021-06-08 4 A 0 12658 0.00 A 29680 D Common Stock 3142857 I See footnote Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting. The reportable securities are directly owned by Aisling Capital IV, LP ("Aisling"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose. /s/ Michael Loiacono, Attorney-in-Fact 2021-06-10